125 related articles for article (PubMed ID: 8410999)
1. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
Mitch CH; Leander JD; Mendelsohn LG; Shaw WN; Wong DT; Cantrell BE; Johnson BG; Reel JK; Snoddy JD; Takemori AE
J Med Chem; 1993 Oct; 36(20):2842-50. PubMed ID: 8410999
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.
Zimmerman DM; Leander JD; Cantrell BE; Reel JK; Snoddy J; Mendelsohn LG; Johnson BG; Mitch CH
J Med Chem; 1993 Oct; 36(20):2833-41. PubMed ID: 8410998
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
5. The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat.
Shaw WN; Mitch CH; Leander JD; Mendelsohn LG; Zimmerman DM
Int J Obes; 1991 Jun; 15(6):387-95. PubMed ID: 1653188
[TBL] [Abstract][Full Text] [Related]
6. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
[TBL] [Abstract][Full Text] [Related]
7. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
Thomas JB; Atkinson RN; Rothman RB; Fix SE; Mascarella SW; Vinson NA; Xu H; Dersch CM; Lu Y; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2001 Aug; 44(17):2687-90. PubMed ID: 11495579
[TBL] [Abstract][Full Text] [Related]
8. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
[TBL] [Abstract][Full Text] [Related]
9. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
Emmerson PJ; McKinzie JH; Surface PL; Suter TM; Mitch CH; Statnick MA
Eur J Pharmacol; 2004 Jun; 494(2-3):121-30. PubMed ID: 15212965
[TBL] [Abstract][Full Text] [Related]
10. Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.
Runyon SP; Brieaddy LE; Mascarella SW; Thomas JB; Navarro HA; Howard JL; Pollard GT; Carroll FI
J Med Chem; 2010 Jul; 53(14):5290-301. PubMed ID: 20568781
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
[TBL] [Abstract][Full Text] [Related]
12. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
[TBL] [Abstract][Full Text] [Related]
13. Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the kappa 2B (enkephalin-sensitive) binding site.
Rothman RB; Xu H; Char GU; Kim A; De Costa BR; Rice KC; Zimmerman DM
Peptides; 1993; 14(1):17-20. PubMed ID: 8382809
[TBL] [Abstract][Full Text] [Related]
14. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
Shaw WN
Pharmacol Biochem Behav; 1993 Nov; 46(3):653-9. PubMed ID: 8278442
[TBL] [Abstract][Full Text] [Related]
16. Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: comparison with the distribution of mu, delta and kappa binding sites.
Gackenheimer SL; Suter TM; Pintar JE; Quimby SJ; Wheeler WJ; Mitch CH; Gehlert DR; Statnick MA
Neuropeptides; 2005 Dec; 39(6):559-67. PubMed ID: 16289278
[TBL] [Abstract][Full Text] [Related]
17. Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582.
Sahr AE; Sindelar DK; Alexander-Chacko JT; Eastwood BJ; Mitch CH; Statnick MA
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R463-71. PubMed ID: 18525013
[TBL] [Abstract][Full Text] [Related]
18. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.
Need AB; McKinzie JH; Mitch CH; Statnick MA; Phebus LA
Life Sci; 2007 Oct; 81(17-18):1389-96. PubMed ID: 17935738
[TBL] [Abstract][Full Text] [Related]
19. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
